Synergistic GPCR Heteromer Inhibitors for Cancer Treatment

A novel system combining GPCR heteromer inhibitors with AI, IoT, blockchain, and advanced materials to create a more effective and personalized cancer treatment approach.

The original patent disclosed inhibitors of novel, functional GPCR heteromers, specifically CXCR4-HRH1 heteromers, which are involved in cancer progression. However, the patent's approach has limitations in terms of patient identification, treatment optimization, and data management. The new inventive concept addresses these limitations by integrating the patented inhibitors with distinct technologies to create a more powerful system.

The new system consists of a CXCR4 inhibitor, a HRH1 inhibitor, and an AI-powered diagnostic module for identifying patients with CXCR4-HRH1 heteromers. The AI module is trained on a dataset of cancer patient biopsies and genomic data, enabling personalized treatment. Additionally, the system incorporates blockchain technology to securely store and manage patient data and treatment outcomes. Furthermore, nanoparticles comprising CXCR4-binding and HRH1-binding peptides are designed to target CXCR4-HRH1 heteromers in cancer cells, enhancing treatment efficacy. An IoT-enabled device tracks patient vital signs and biomarkers, connecting to a cloud-based analytics platform for data analysis. The system also utilizes machine learning algorithms to identify new therapeutic targets for cancer treatment and a CRISPR-Cas9 genome editing system to validate their therapeutic potential.

The new claims introduce a synergistic combination of GPCR heteromer inhibitors with AI, IoT, blockchain, and advanced materials, which is not obvious from the original patent. The integration of these distinct technologies creates a novel system that provides a more effective and personalized cancer treatment approach.

Alternative embodiments of the inventive concept may include using different AI algorithms, varying the design of the nanoparticles, or incorporating additional technologies such as virtual or augmented reality for patient monitoring. Variations may also include applying the system to different types of cancer or expanding the diagnostic module to identify other GPCR heteromers.

The synergistic GPCR heteromer inhibitors system has significant commercial potential in the cancer treatment market, offering a more effective and personalized approach to cancer care. The system's ability to integrate with emerging technologies such as AI, IoT, and blockchain also positions it for adoption in the rapidly growing digital health industry.